[P3–018]: A SUMMARY OF BASELINE EFFICACY CHARACTERISTICS FROM THE MINDSET STUDY: A GLOBAL PHASE 3 STUDY OF INTEPIRDINE (RVT‐101) IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER's DISEASE. (1st July 2017)